Systemic lupus erythematosus (SLE) is the prototype of autoimmune diseases with multiorgan involvement. SLE presents many genetic and epigenetic associations and the pathogenesis is characterized by a complex network of alterations affecting both adaptative and innate immunity. The disclosure of novel mechanisms of SLE pathogenesis suggested new therapeutic targets, based on interference with the cytokine pathways or on depletion of the immune cells.
RahmanAIsembergDA. Systemic lupus erythematosus. N Engl J Med2008; 58:929–39.
2.
Pons-EstelGJAlarcónGSSconfieldLReinlibLCooperGS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum2010; 39(4):257–68.
3.
FlesherDLSunXBehrensTWGrahamRRCriswellLA. Recent advances in the genetics of systemic lupus erythematosus. Expert Rev Clin Immunol2010; 6:461–79.
4.
CrowMK. Collaboration, genetic associations and lupus erythematosus. N Eng J Med2008; 358:956–61.
5.
MonticieloOAMucenicTMachado XavierRTavares BrenolJCBogo ChiesJA. The role of mannose-binding lectin in systemic lupus erythematosus. Clin Rheumatol2008; 27:413–19.
6.
RönnblomLAimGVElorantaML. The type I interferon system in the development of lupus. Semin Immunol2011; 23:113–21.
RichardsonBScheinbartLStrahlerJGrossLHanashSJohnsonM. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum1990; 33(11):1665–73.
9.
ZhangYZhaoMSawalhaAHRichardsonBLuQ. Impaired DNA methylation and its mechanisms in CD4(+)T cells of systemic lupus erythematosus. J Autoimmun2013; 41:92–99.
10.
ZhaoSLongHQiaanjinL. Epigenetic perspectives in systemic lupus erythematosus: pathogenesis, biomarkers and therapeutic potentials. Clinic Rev Allerg Immunol2010; 39:3–9.
11.
StagakisEBertsiasGVerginisPNakouMHatziapostolouMKritikosHIliopoulosDBoumpasDT. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: mir-21 regulates aberrant T-cells response trough the regulation of PDCD4 expression. Ann Rheum Dis2011; 70:1496–506.
12.
WeckerleCENiewoldTB. The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clinic Rev Allerg Immunol2011; 40:42–49.
13.
ShoenfeldYTincaniAGershwinME. Sex gender and autoimmunity. Autoimmun Rev2012; 38(2–3):J71–3.
14.
DoriaACanovaMTononM. Infections as trigger and complications of systemic lupus erythematosus. Autoimmun Rev2008; 8:24–28.
15.
Zandman-GoddardGSolomonMRosmanZPeevaEShoenfeldY. Environment and lupus-related diseases. Lupus2012; 21(3):241–50.
16.
WallingHWSontheimerRD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol2009; 10:365–81.
17.
PisetskyDSUllalAJ. The blood nucleome in the pathogenesis of SLE. Autoimmun Rev2010; 10:35–37.
18.
GerliRNocentiniGAlunnoABocciEBBianchiniRBistoniORiccardiC. Identification of regulatory T cells in systemic lupus erythematosus. Autoimmun Rev2009; 8:426–30.
19.
MaCYJiaoYLZhangJYangQRZhangZFShenYJChenZJZhaoYR. Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus. Rheumatol Int2012; 32:395–402.
20.
FransenJHvan der VlagJRubenJAdemaGJBerdenJHHilbrandsLB. The role of dendritic cells in the pathogenesis of systemic lupus erythematosus. Arthritis Res Ther2010; 12:207.
21.
PengSL. Altered T and B lymphocyte signaling pathways in lupus. Autoimmun Rev2009; 8:179–83.
22.
SavinoMTUlivieriCEmmiG. The She family protein adaptor, Rai, acts as a negative regulator of Th17 and Th1 cell development. J Leukoc Biol2013; 93(4):549–59.
23.
ApostolidisSALiebermanLAKis-TothKCrispínJCTsokosGC. The dysregulation of cytokine networks in systemic lupus erythematosus. J Interferon Cytokine Res2011; 31:769–79.
24.
JacobNStohlW. Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther2011; 13:228.
25.
ChuVTEnghardPSchurerSSteinhauserGRudolphBRiemekastenGBerekC. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum2009; 60:2083–93.
26.
Yildirim-TorunerCDiamondB. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol2011; 127:303–12.
27.
RovinBHFurieRLatinisK; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum2012; 64:1215–26.
28.
MokMY. The immunological basis of B-cell therapy in systemic lupus erythematosus. Int J Rheum Dis2010; 13:3–11.
29.
MokCC. Abatacept for systemic lupus erythematosus: the outlook. Expert Opin Biol Ther2012; 12(12):1559–61.
30.
StohlWScholzJLCancroMP. Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside. Curr Opin Rheumatol2011; 23:305–10.
31.
Merrill JT, Ginzler EM, Wallace DJ et al. on Behalf of the LBSL02/99 Study Group. Long-term safety profile of Belimumab plus standard therapy in patients with SLE. Arthritis Rheum2012; 64(10):3364–73.
32.
GinzlerEMWaxSRajeswaranACoptSHillsonJRamosESingerNG. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther2012; 7;14(1):R33.
33.
AringerMSmolenJS. TNF inhibition in SLE: where do we stand?Lupus2009; 18:5–8.
34.
Dall'eraMChakravartyEF. Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies. Curr Rheumatol Rep2011; 13(4):308–16.
35.
LichtmanAIHelfgottSMKriegelMA. Emerging therapies for systemic lupus erythematosus — Focus on targeting interferon-alpha. Clin Immunol2012; 143:210–21.
